Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ImmunoPrecise Antibodies (IPA)
NASDAQ:IPA
RESEARCH TOOLSreports
Holding IPA?
Track your performance easily
IPA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.32 - $2.60
Previous Close$0.38
Volume269.10K
Average Volume (3M)522.01K
Market Cap
$10.50M
Enterprise Value$17.36M
Total Cash (Recent Filing)C$3.91M
Total Debt (Recent Filing)C$13.50M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Dec 12, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding27,300,000
10 Day Avg. Volume481,983
30 Day Avg. Volume522,011
Standard Deviation0.25
R-Squared0.00327
Alpha-0.00314
Financial Highlights & Ratios
Price to Book (P/B)0.32
Price to Sales (P/S)0.62
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.00Price Target Upside2256.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
ImmunoPrecise Antibodies News
PremiumCompany Announcements
ImmunoPrecise Antibodies Advances in Cancer Therapy Development
PremiumCompany Announcements
ImmunoPrecise Antibodies Hosts TECHDAY on AI Innovations
PremiumCompany Announcements
ImmunoPrecise Advances in Anti-Aging Research with Mayo ClinicPremiumCompany Announcements
ImmunoPrecise Antibodies Announces Annual Meeting Plans
PremiumCompany Announcements
ImmunoPrecise Antibodies to Join AI Drug Summit
PremiumCompany Announcements
ImmunoPrecise Sets Virtual AGM for November 2024
PremiumCompany Announcements
ImmunoPrecise Heralds Nobel Win, AI-Driven Biotherapeutics
PremiumCompany Announcements
ImmunoPrecise Advances Cancer Therapy with Biotheus PartnershipOwnership Overview
1.20% Insiders
0.06% Mutual Funds
5.88% Other Institutional Investors
92.85% Public Companies and
Individual Investors
IPA FAQ
What was ImmunoPrecise Antibodies’s price range in the past 12 months?
ImmunoPrecise Antibodies lowest stock price was $0.32 and its highest was $2.60 in the past 12 months.
What is ImmunoPrecise Antibodies’s market cap?
Currently, no data Available
When is ImmunoPrecise Antibodies’s upcoming earnings report date?
ImmunoPrecise Antibodies’s upcoming earnings report date is Dec 12, 2024 which is in 17 days.
How were ImmunoPrecise Antibodies’s earnings last quarter?
ImmunoPrecise Antibodies released its earnings results on Sep 16, 2024. The company reported -$0.107 earnings per share for the quarter, missing the consensus estimate of -$0.079 by -$0.029.
Is ImmunoPrecise Antibodies overvalued?
According to Wall Street analysts ImmunoPrecise Antibodies’s price is currently Undervalued.
Does ImmunoPrecise Antibodies pay dividends?
ImmunoPrecise Antibodies does not currently pay dividends.
What is ImmunoPrecise Antibodies’s EPS estimate?
ImmunoPrecise Antibodies’s EPS estimate is -$0.07.
How many shares outstanding does ImmunoPrecise Antibodies have?
ImmunoPrecise Antibodies has 27,915,562 shares outstanding.
What happened to ImmunoPrecise Antibodies’s price movement after its last earnings report?
ImmunoPrecise Antibodies reported an EPS of -$0.107 in its last earnings report, missing expectations of -$0.079. Following the earnings report the stock price went down -19.403%.
Which hedge fund is a major shareholder of ImmunoPrecise Antibodies?
Currently, no hedge funds are holding shares in IPA
---
ImmunoPrecise Antibodies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (2256.02% Upside)
$9.00 (2256.02% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.3%
Last 30 Days ▲ 10.7%
Last 30 Days ▲ 10.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.51%
12-Months-Change
Fundamentals
Return on Equity
-62.82%
Trailing 12-Months
Asset Growth
-26.22%
Trailing 12-Months
Company Description
ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd. engages in the provision of integrated antibody solutions. It services include human monoclonals, hybridoma development, rabbit monoclonals, b-cell select, phage display, cryostorage, hybridoma sequencing, antibody generation, anti-body purification, polyclonal production, and peptide production. The company was founded by Robert Beecroft in 1989 and is headquartered in Victoria, Canada.
---
IPA Earnings Call
Q1 2024
0:00 / 0:00
---
IPA Stock 12 Month Forecast
Average Price Target
$9.00
▲(2256.02% Upside)
Technical Analysis
Best Analysts Covering IPA
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-61.29%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -61.29% per trade.
---